LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

158.84 2.08

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

151.25

Max

160.6

Galvenie mērījumi
By Trading Economics
Ienākumi	262M -15M
Pārdošana	1.6M 996M
EPS	2.06
Peļņas marža	-1.486
Darbinieki	18,300
EBITDA	-11M 187M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+31.63% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.3B 7.2B
Iepriekšējā atvēršanas cena	156.76
Iepriekšējā slēgšanas cena	158.84

Ziņu noskaņojums

By Acuity

20%

80%

31 / 345 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. maijs 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Conduent to Sell Public Transit Business to Modaxo for $164 Million

2026. g. 21. maijs 16:49 UTC

Peļņas

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

2026. g. 21. maijs 16:26 UTC

Galvenie tirgus virzītāji

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

2026. g. 21. maijs 23:51 UTC

Tirgus saruna

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

2026. g. 21. maijs 23:37 UTC

Peļņas

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

2026. g. 21. maijs 23:37 UTC

Peļņas

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

2026. g. 21. maijs 23:37 UTC

Peļņas

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

2026. g. 21. maijs 23:34 UTC

Tirgus saruna

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

2026. g. 21. maijs 23:30 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 21. maijs 23:30 UTC

Tirgus saruna

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

2026. g. 21. maijs 22:33 UTC

Iegādes, apvienošanās, pārņemšana

Conduent to Sell Public Transit Business to Modaxo for $164M

2026. g. 21. maijs 21:53 UTC

Peļņas

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

2026. g. 21. maijs 21:02 UTC

Peļņas

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

2026. g. 21. maijs 20:55 UTC

Peļņas

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

2026. g. 21. maijs 20:30 UTC

Karstas akcijas

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

2026. g. 21. maijs 20:20 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. maijs 20:20 UTC

Tirgus saruna

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

2026. g. 21. maijs 20:20 UTC

Peļņas

Webull 1Q Adj EPS 3c >BULL

2026. g. 21. maijs 20:20 UTC

Peļņas

Webull 1Q Rev $159.9M >BULL

2026. g. 21. maijs 20:18 UTC

Tirgus saruna

Mexico's Inflation Seen Easing in Early May -- Market Talk

2026. g. 21. maijs 20:18 UTC

Peļņas

Webull 1Q Loss/Shr 4c

2026. g. 21. maijs 19:43 UTC

Tirgus saruna

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

2026. g. 21. maijs 19:33 UTC

Tirgus saruna

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

2026. g. 21. maijs 18:58 UTC

Peļņas

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

2026. g. 21. maijs 18:15 UTC

Tirgus saruna

Gold Higher For Second Consecutive Day -- Market Talk

2026. g. 21. maijs 17:40 UTC

Tirgus saruna

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

2026. g. 21. maijs 17:04 UTC

Tirgus saruna

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

2026. g. 21. maijs 17:01 UTC

Peļņas

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

2026. g. 21. maijs 16:20 UTC

Tirgus saruna

Peļņas

Stellantis Targets Distant but Constructive -- Market Talk

2026. g. 21. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

31.63% augšup

Prognoze 12 mēnešiem

Vidējais 205.38 USD 31.63%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

31 / 345 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.